Virtual Poster Session From San Francisco - prIME Oncology
Virtual Poster
Virtual Poster

Virtual Poster Session From San Francisco

Practical Application of Key Data Presented During the 2019 Gastrointestinal Cancers Symposium

View Activities

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

View virtual poster presentations and downloadable slides covering the most up-to-date clinical trial data from the 2019 Gastrointestinal Cancers Symposium in San Francisco.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

Feb 1, 2019

Expiration Date

Feb 1, 2020

HCC

Ghassan Abou-Alfa, MD, MBA

Abstract 423: Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)

Featured Expert: Ghassan Abou-Alfa, MD, MBA

Ghassan Abou-Alfa, MD, MBA

Abstract 207: Quality-adjusted life years assessment using cabozantinib for patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial

Featured Expert: Ghassan Abou-Alfa, MD, MBA

Anne Demols, MD, PhD

Abstract 345: Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tumors: A randomized double-blinded placebo-controlled phase II trial

Featured Expert: Anne Demols, MD, PhD

Thomas Yau, MBBS, MRCP, FHKCP, FHKAM

Abstract 361: Outcomes of tyrosine kinase inhibitors (TKI) after immunotherapy in unresectable or advanced hepatocellular carcinoma (HCC) patients

Featured Expert: Thomas Yau, MBBS, MRCP, FHKCP, FHKAM

Masatoshi Kudo, MD, PhD

Abstract 186: Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT)

Featured Expert: Masatoshi Kudo, MD, PhD

CRC

Andrew B. Nixon, PhD, MBA

Abstract 587: Blood-based biomarkers in metastatic colorectal cancer patients treated with FOLFIRI plus regorafenib or placebo: Results from LCCC1029.

Featured Expert: Andrew B. Nixon, PhD, MBA

Michael Sangmin Lee, MD

Abstract 597: Association of consensus molecular subtypes (CMS) with time to progression (TTP), progression free survival (PFS), and overall survival (OS) with second-line FOLFIRI ± regorafenib in metastatic colorectal cancer (mCRC).

Featured Expert: Michael Sangmin Lee, MD

Michel Ducreux, MD, PhD

Abstract 539: Outcomes by tumor location in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): Final analysis from the prospective, observational CORRELATE study.

Featured Expert: Michel Ducreux, MD, PhD

Mark Yarchoan, MD

Abstract 563: A phase II study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair–proficient (MMR-p) advanced colorectal cancer

Featured Expert: Mark Yarchoan, MD

Carl Christoph Schimanski, MD, PhD

Abstract 480: A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results.

Featured Expert: Carl Christoph Schimanski, MD, PhD

Neil H. Segal, MD, PhD

Abstract 670: Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability–high (MSI-H) tumors

Featured Expert: Neil H. Segal, MD, PhD

  • Ghassan Abou-Alfa, MD, MBAMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Anne Demols, MD, PhD Erasme University Hospital
    Brussels, Belgium
  • Michel Ducreux, MD, PhDGustave Roussy
    Villejuif, France
  • Charalampos S. Floudas, MD, DMSc, MSNational Cancer Institute
    Washington DC, United States
  • Masatoshi Kudo, MD, PhDKinki University Medical Center
    Osaka, Japan
  • Michael Sangmin Lee, MDUniversity of North Carolina
    Chapel Hill, North Carolina, United States
  • Andrew B. Nixon, PhD, MBADuke Cancer Institute
    Durham, North Carolina, United States
  • Carl Christoph Schimanski, MD, PhDKlinikum Darmstadt
    Darmstadt, Germany
  • Neil H. Segal, MD, PhDMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Thomas Yau, MBBS, MRCP, FHKCP, FHKAMThe University of Hong Kong Queen Mary Hospital
    Hong Kong Island, Hong Kong
  • Mark Yarchoan, MDJohns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland, United States

This activity is specifically designed to meet the needs of practicing medical oncologists and other healthcare professionals involved in the treatment of patients with gastrointestinal malignancies.

After successful completion of this educational activity, participants should be able to:

  • Discuss key data from the conference
  • Apply key data from the conference to clinical practice, as appropriate

This educational activity is supported by grants from Bayer and Ipsen.

Independent Medical Education (IME)

This IME activity is organized by prIME, a Medscape Oncology Company. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME, a Medscape Oncology Company.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME, a Medscape Oncology Company assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME, a Medscape Oncology Company for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME, a Medscape Oncology Company is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Abou-Alfa has disclosed that he has received consulting fees from 3DMedcare, Agios, Alignmed, Amgen, Antengene, Aptus, Aslan, Astellas, AstraZeneca, Bayer, BeiGene, Bristol-Myers Squibb, Boston Scientific, Bridgebio, CARsgen, Celgene, CASI, Cipla, Daiichi, Debio, Delcath, Eisai, Exelixis, Genoscience, Halozyme, Hengrui, Incyte, Inovio, Ipsen, Jazz, Kyowa Kirin, LAM, Lilly, Merck, Mina, Novella, Onxeo, PCI Biotech, QED, Redhill, Sanofi, Servier, Sillajen, Tekmira, TwoXAR, Vicus, Yakult, and Yiviva. His spouse has received consulting fees from Aptus, Bioline, Bristol-Myers Squibb, Celgene, CytomX, Gilead, Halozyme, Janssen, Newlink Genetics, Loxo, Pfizer, Pharmacyte, Pharmacyclics, Pieris, Sanofi, Silenseed, Sobi, Targovax, and TwoXAR. He has performed contracted research for Agios, Array, AstraZeneca, Bayer, BeiGene, Bristol-Myers Squibb, CASI, Exelixis, Halozyme, Incyte, Lilly, Novartis, Polaris Puma, and QED. His spouse has performed contracted research for Acta Biologica, AstraZeneca, Bristol-Myers Squibb, Celgene, Genentech, Halozyme, MabVax, OncoQuest, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Demols has disclosed that she has received consulting fees from Bayer, Ipsen, and Merck. She has also performed contracted research for Bayer funding. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Ducreux has disclosed that he has received consulting fees from Amgen, Bayer, Lilly, Merck, Merck Serono, Roche, and Servier. He has also performed contracted research for Merck Serono and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kudo has disclosed that he has received consulting fees from Bayer, Bristol-Myers Squibb, Eisai, and Merck Sharp & Dohme Corp. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Lee has disclosed that he has received consulting fees from AstraZeneca. He has also performed contracted research for Amgen, Bristol-Myers Squibb, EMD Serono, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Nixon has disclosed that he has received consulting fees from Eli Lilly and Kanghong Pharma. He has also performed contracted research for Acceleron Pharma, Genentech, Leadiant Biosciences, MedPacto, Seattle Genetics, Sanofi-Aventis, and Tracon Pharma. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Schimanski has disclosed contracted research for Merck KGaA. He has also received a travel grant from Gilead. He has also disclosed that his spouse receives salary from Merck KGaA. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Segal has disclosed that he has received consulting fees from Bristol-Myers Squibb, Chugai, CStone Pharmaceuticals, EMD Serono, Gritstone Oncology, Horizon Pharma, IFM therapeutics, Kyn Therapautics, MedImmune/AstraZeneca, Merck, Pfizer, Pieris, PsiOxus, PureTech Ventures, Roche/Genentech, Synlogic, and TRM Oncology. He has also performed contracted research with Bristol-Myers Squibb, Incyte, MedImmune/AstraZeneca, Merck, Pfizer, and Roche/Genentech. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Yarchoan has disclosed that he has received consulting fees from Eisai and Exelixis. He has also received grants from Bristol-Myers Squibb, Exelixis, and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Yau has disclosed that he has received consulting fees from Bayer, Bristol-Myers Squibb, Eisai, and Merck Sharp & Dohme Corp. He has also performed contracted research for Bayer and Bristol-Myers Squibb. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME, a Medscape Oncology Company have disclosed:

  • Amy Furedy, RN, OCN (scientific content manager) – no relevant financial relationships
  • Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.